InvestSMART

Lumos Diagnostics Holdings Limited (ASX: LDX) - Announcements

- Current share price for LDX : $0.060

ASX company news and announcements for Lumos Diagnostics Holdings Limited (LDX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Lumos Diagnostics Holdings Limited (LDX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Lumos Diagnostics Holdings Limited (LDX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Lumos Diagnostics Holdings Limited (LDX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$58 Change in substantial holding from RYD 9 Oct 2024 4:29PM $0.043 $0.060 risen by 39.53%
$58 Lumos and BARDA Partnership - Investor Briefing 9 Oct 2024 3:31PM $0.043 $0.060 risen by 39.53%
$58 Notification regarding unquoted securities - LDX 9 Oct 2024 11:45AM $0.042 $0.060 risen by 42.86%
$58 Application for quotation of securities - LDX 9 Oct 2024 11:39AM $0.042 $0.060 risen by 42.86%
$58 Lumos Successfully Completes Retail Entitlement Offer 8 Oct 2024 8:52AM $0.041 $0.060 risen by 46.34%
$58 Lumos and BARDA Partner to Support FebriDx CLIA Waiver Study 3 Oct 2024 9:33AM $0.037 $0.060 risen by 62.16%
$58 Lumos Awarded National Contract with MediGroup for FebriDx 25 Sep 2024 12:23PM $0.038 $0.060 risen by 57.89%
$58 Ceasing to be a substantial holder 23 Sep 2024 4:18PM $0.034 $0.060 risen by 76.47%
$58 Change in substantial holding from RYD 23 Sep 2024 2:35PM $0.034 $0.060 risen by 76.47%
$58 Investor Roadshow Presentation 23 Sep 2024 9:43AM $0.033 $0.060 risen by 81.82%
$58 Lumos Achieves First Phase 2 Milestone in Hologic Agreement 20 Sep 2024 10:11AM $0.034 $0.060 risen by 76.47%
$58 Change in substantial holding 19 Sep 2024 4:43PM $0.033 $0.060 risen by 81.82%
$58 Change in substantial holder 16 Sep 2024 2:12PM $0.034 $0.060 risen by 76.47%
$58 Change in substantial holding 16 Sep 2024 10:54AM $0.036 $0.060 risen by 69.01%
$58 Lumos Appoints Thermo Fisher Scientific as US Distributor 16 Sep 2024 9:28AM $0.034 $0.060 risen by 76.47%
$58 Change in substantial holding from RYD 13 Sep 2024 3:52PM $0.035 $0.060 risen by 71.43%
$58 Application for quotation of securities - LDX 12 Sep 2024 10:50AM $0.035 $0.060 risen by 71.43%
$58 Letter to Ineligible Shareholders 11 Sep 2024 9:02AM $0.038 $0.060 risen by 60%
$58 Letter to Eligible Shareholders 11 Sep 2024 9:02AM $0.038 $0.060 risen by 60%
$58 Retail Entitlement Offer Booklet 11 Sep 2024 9:01AM $0.038 $0.060 risen by 60%
$58 Retail Entitlement Offer Opens 11 Sep 2024 9:01AM $0.038 $0.060 risen by 60%
$58 Lumos Successfully Completes Institutional Entitlement Offer 6 Sep 2024 8:54AM $0.046 $0.060 risen by 30.43%
$58 Becoming a substantial holder 4 Sep 2024 2:39PM $0.046 $0.060 risen by 30.43%
$58 Ceasing to be a substantial holder 4 Sep 2024 12:00PM $0.046 $0.060 risen by 30.43%
$58 Proposed issue of securities - LDX 4 Sep 2024 10:53AM $0.046 $0.060 risen by 30.43%

201 - 225 of 566 results

Page 9 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.